Tango Therapeutics, Inc. (TNGX)
22.89
+0.70
(+3.13%)
USD |
NASDAQ |
Oct 27, 16:00
23.00
+0.11
(+0.48%)
After-Hours: 20:00
Tango Therapeutics Enterprise Value : 2.872B for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 2.872B |
| October 26, 2026 | 2.755B |
| October 23, 2026 | 2.948B |
| October 22, 2026 | 3.721B |
| October 21, 2026 | 3.561B |
| October 20, 2026 | 3.270B |
| October 19, 2026 | 2.980B |
| October 16, 2026 | 2.729B |
| October 15, 2026 | 2.840B |
| October 14, 2026 | 2.754B |
| October 13, 2026 | 2.759B |
| October 12, 2026 | 3.088B |
| October 09, 2026 | 3.027B |
| October 08, 2026 | 2.818B |
| October 07, 2026 | 2.694B |
| October 06, 2026 | 2.706B |
| October 05, 2026 | 2.904B |
| October 02, 2026 | 2.931B |
| October 01, 2026 | 3.135B |
| September 30, 2026 | 3.219B |
| September 29, 2026 | 3.130B |
| September 28, 2026 | 3.110B |
| September 25, 2026 | 3.214B |
| September 24, 2026 | 3.165B |
| September 23, 2026 | 3.135B |
| Date | Value |
|---|---|
| September 22, 2026 | 3.317B |
| September 21, 2026 | 2.778B |
| September 18, 2026 | 2.680B |
| September 17, 2026 | 2.973B |
| September 16, 2026 | 2.950B |
| September 15, 2026 | 3.041B |
| September 14, 2026 | 3.150B |
| September 11, 2026 | 3.022B |
| September 10, 2026 | 2.953B |
| September 09, 2026 | 3.059B |
| September 08, 2026 | 2.840B |
| September 04, 2026 | 2.810B |
| September 03, 2026 | 2.850B |
| September 02, 2026 | 2.776B |
| September 01, 2026 | 2.781B |
| August 31, 2026 | 2.864B |
| August 28, 2026 | 2.948B |
| August 27, 2026 | 3.275B |
| August 26, 2026 | 3.307B |
| August 25, 2026 | 3.189B |
| August 24, 2026 | 3.145B |
| August 21, 2026 | 3.039B |
| August 20, 2026 | 2.977B |
| August 19, 2026 | 3.261B |
| August 18, 2026 | 3.302B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 1.666B |
| NovelStem International Corp. | 2.047M |
| Brainstorm Cell Therapeutics, Inc. | 9.873M |
| Summit Therapeutics, Inc. | 11.49B |
| Kezar Life Sciences, Inc. | -11.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -55.34M |
| Total Expenses (Quarterly) | 55.34M |
| EPS Diluted (Quarterly) | -0.3692 |
| Earnings Yield | -3.66% |
| Normalized Earnings Yield | -3.659 |